Quizartinib Receives Orphan Drug Designation for FLT3-Mutated AML in Japan

Quizartinib receives Orphan Drug designation for FLT3-mutated AML in Japan

TOKYO and MUNICH and BASKING RIDGE, N.J., September 11, 2018  -- The Japan Ministry of Health, Labour and Welfare (MHLW) has granted quizartinib (AC220, Daiichi Sankyo), an investigational inhibitor of FLT3, the Orphan Drug designation for the treatment of acute myeloid leukaemia (AML) harbouring FLT3-mutations.

CAR-TCR Summit 2018: Preliminary first-in-human data with CAR-Claudin18.2-T in gastric and pancreatic cancer

CARsgen Therapeutics, a Shanghai-based clinical-stage immune-oncology company committed to developing Chimeric Antigen Receptor T (CAR-T) cell therapies for cancer, presented preliminary data of their first-in-class CAR-Claudin18.2 T-cell clinical trial in pancreatic and gastric cancer patients during the 2018 CAR-TCR Summit in Boston.

DRIVER connects cancer patients in China and the United States to the best care

SAN FRANCISCO and SHANGHAI, Sept. 6, 2018/PRNewswire/ -- Today, Driver, a global technology platform that connects cancer patients to the best treatments, launches in the United States and China. Driver's platform enables any patient, anywhere in the world, to access treatment options across an unprecedented network of cancer centres without leaving home.

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient's immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

PolyU Researchers Develop Novel Self-fitting Scaffold for Bone-Regeneration

HONG KONG, August 15, 2018 /PRNewswire/ -- A group of researchers from the Hong Kong Polytechnic University (PolyU) in close collaboration with Sichuan University have successfully designed and manufactured a novel bone scaffold that can be safely implanted into bone defects, induce bone-regeneration, and enhance the recovery of bone injuries and fractures.

Pan-EGFR TKI pirotinib has commenced into Phase II clinical testing in China

HONG KONG, CHINA - 13 August 2018 - Sihuan Pharmaceutical Holdings Group Ltd. (HKEx: 0460), announced that its innovative in-house developed oncology drug pirotinib has commenced into Phase II Clinical testing in China following the completion of a Phase I clinical trial in three renowned cancer research centres in the United States.